Cinkajzlová A, Lacinová Z, Kloučková J, Kaválková P, Trachta P, Kosák M, Krátký J, Kasalický M, DoleŽalová K, Mráz M, Haluzík M
Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital, Prague, Czech Republic, Centre for Experimental Medicine and Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Physiol Res. 2017 Sep 22;66(4):641-652. doi: 10.33549/physiolres.933522. Epub 2017 Apr 12.
CD163 is a marker of macrophages with anti-inflammatory properties and its soluble form (sCD163) is considered a prognostic predictor of several diseases including type 2 diabetes mellitus (T2DM). We explored sCD163 levels at baseline and after very low-calorie diet (VLCD) or bariatric surgery in 32 patients with obesity (20 undergoing VLCD and 12 bariatric surgery), 32 obese patients with T2DM (22 undergoing VLCD and 10 bariatric surgery), and 19 control subjects. We also assessed the changes of CD163 positive cells of monocyte-macrophage lineage in peripheral blood and subcutaneous adipose tissue (SAT) in subset of patients. Plasma sCD163 levels were increased in obese and T2DM subjects relative to control subjects (467.2+/-40.2 and 513.8+/-37.0 vs. 334.4+/-24.8 ng/ml, p=0.001) and decreased after both interventions. Obesity decreased percentage of CD163+CD14+ monocytes in peripheral blood compared to controls (78.9+/-1.48 vs. 86.2+/-1.31 %, p=0.003) and bariatric surgery decreased CD163+CD14+HLA-DR+ macrophages in SAT (19.4+/-2.32 vs. 11.3+/-0.90 %, p=0.004). Our data suggest that increased basal sCD163 levels are related to obesity and its metabolic complications. On the contrary, sCD163 or CD163 positive cell changes do not precisely reflect metabolic improvements after weight loss.
CD163是具有抗炎特性的巨噬细胞标志物，其可溶性形式（sCD163）被认为是包括2型糖尿病（T2DM）在内的多种疾病的预后预测指标。我们对32例肥胖患者（20例接受极低热量饮食，12例接受减肥手术）、32例肥胖合并T2DM患者（22例接受极低热量饮食，10例接受减肥手术）和19例对照受试者，在基线、极低热量饮食（VLCD）或减肥手术后的sCD163水平进行了探究。我们还评估了部分患者外周血和皮下脂肪组织（SAT）中单核细胞 - 巨噬细胞系CD163阳性细胞的变化。肥胖和T2DM受试者的血浆sCD163水平相对于对照受试者升高（467.2±40.2和513.8±37.0 vs. 334.4±24.8 ng/ml，p = 0.001），且两种干预后均降低。与对照组相比，肥胖使外周血中CD163 + CD14 +单核细胞百分比降低（78.9±1.48 vs. 86.2±1.31%，p = 0.003），减肥手术使SAT中CD163 + CD14 + HLA - DR +巨噬细胞减少（19.4±2.32 vs. 11.3±0.90%，p = 0.004）。我们的数据表明，基础sCD163水平升高与肥胖及其代谢并发症相关。相反，sCD163或CD163阳性细胞变化并不能准确反映体重减轻后的代谢改善情况。
